Lord's Mark Microbiotech to Launch Saliva-Based Organ Age Test

This test, priced between INR 15,000 and 20,000, aims to provide a more affordable alternative to current market options, which range from INR 30,000 to 40,000. 

Lord’s Mark Microbiotech, a subsidiary of Lord’s Mark Industries, has launched a new saliva-based test designed to assess the biological age of organs. 

This test, priced between INR 15,000 and 20,000, aims to provide a more affordable alternative to current market options, which range from INR 30,000 to 40,000. 

The organ age test uses epigenetic markers to evaluate how the biological age of an individual’s organs compares with their chronological age. The company hopes this will enable early identification of potential health issues and guide preventive measures. 

Subodh Gupta, CEO of Lord’s Mark Microbiotech, said, "If we identify that an organ's age is higher than the person's chronological age, we can recommend lifestyle changes, supplements, and other interventions to reverse this condition potentially." 

He added that the test will offer a 99.6% accuracy rate and a broader range of features compared to existing options.

Lord’s Mark Microbiotech has set a revenue target of INR 100 Cr within the next two years. The company currently offers a variety of saliva-based genetic tests that predict the risk of conditions such as cardiovascular diseases and cancers. By analyzing DNA extracted from saliva, these tests provide insights that help individuals take proactive health measures.

Current Offerings

The company's flagship brand, myDNA, includes tests such as myDNA CardioGen for assessing cardiac risk and myDNA OncoGen for screening heritable cancers. 

Other tests under the myDNA brand focus on children’s health, female health, and sports-related conditions.

Gupta noted that the new organ age test will include guidelines for reversing organ aging. The company sells around 3,000 test kits monthly and partners with over 300 hospitals, including KIMS and Ruby Hall. 

It has also signed memoranda of understanding with approximately 150 institutions and hospitals to expand its genetic testing services.

"Our tests are designed to be patient-friendly, requiring only a simple saliva swab instead of blood samples. This approach is particularly advantageous for individuals uncomfortable with blood tests, including young children," Gupta added.